Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder
Background. Castleman’s disease (CD), also known as angiofollicular node hyperplasia, is a rare heterogenous lymphoproliferative disorder. This disease exists as two distinct entities: a localized or unicentric CD (UCD) which has a more benign clinical course and multicentric CD (MCD) which is a sys...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/5235163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564017200103424 |
|---|---|
| author | Jason Hew Fauzia Rana Louise Zhou |
| author_facet | Jason Hew Fauzia Rana Louise Zhou |
| author_sort | Jason Hew |
| collection | DOAJ |
| description | Background. Castleman’s disease (CD), also known as angiofollicular node hyperplasia, is a rare heterogenous lymphoproliferative disorder. This disease exists as two distinct entities: a localized or unicentric CD (UCD) which has a more benign clinical course and multicentric CD (MCD) which is a systemic disease and carries a worse prognosis. MCD is often associated with human immunodeficiency virus (HIV) infection and these patients are usually coinfected with human herpes virus-8 (HHV-8). Rituximab is an anti-CD20 monoclonal antibody that has become integral to the management of this disease. It is used alone or in combination with chemotherapy to treat MCD. Case Report. We describe a case of a 58-year-old man with HIV and HHV-8 MCD and evidence of organ failure with a poor performance status that went into complete remission after four cycles of therapy with weekly rituximab. Conclusion. HIV-MCD can be challenging to diagnose and to manage. Early recognition can reduce morbidity and mortality associated with the disease. Rituximab monotherapy can be used as a safe and effective treatment option in patients with a poor performance status. |
| format | Article |
| id | doaj-art-de8edd9487ec42bd9ae4799b7dc3b2ef |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-de8edd9487ec42bd9ae4799b7dc3b2ef2025-02-03T01:12:06ZengWileyCase Reports in Oncological Medicine2090-67062090-67142017-01-01201710.1155/2017/52351635235163Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative DisorderJason Hew0Fauzia Rana1Louise Zhou2Department of Internal Medicine, Division of Medical Oncology, University of Florida COM, Jacksonville, FL, USADepartment of Internal Medicine, Division of Medical Oncology, University of Florida COM, Jacksonville, FL, USADepartment of Internal Medicine, Division of Medical Oncology, University of Florida COM, Jacksonville, FL, USABackground. Castleman’s disease (CD), also known as angiofollicular node hyperplasia, is a rare heterogenous lymphoproliferative disorder. This disease exists as two distinct entities: a localized or unicentric CD (UCD) which has a more benign clinical course and multicentric CD (MCD) which is a systemic disease and carries a worse prognosis. MCD is often associated with human immunodeficiency virus (HIV) infection and these patients are usually coinfected with human herpes virus-8 (HHV-8). Rituximab is an anti-CD20 monoclonal antibody that has become integral to the management of this disease. It is used alone or in combination with chemotherapy to treat MCD. Case Report. We describe a case of a 58-year-old man with HIV and HHV-8 MCD and evidence of organ failure with a poor performance status that went into complete remission after four cycles of therapy with weekly rituximab. Conclusion. HIV-MCD can be challenging to diagnose and to manage. Early recognition can reduce morbidity and mortality associated with the disease. Rituximab monotherapy can be used as a safe and effective treatment option in patients with a poor performance status.http://dx.doi.org/10.1155/2017/5235163 |
| spellingShingle | Jason Hew Fauzia Rana Louise Zhou Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder Case Reports in Oncological Medicine |
| title | Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder |
| title_full | Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder |
| title_fullStr | Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder |
| title_full_unstemmed | Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder |
| title_short | Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder |
| title_sort | rituximab monotherapy in the management of a rare case of an hiv associated lymphoproliferative disorder |
| url | http://dx.doi.org/10.1155/2017/5235163 |
| work_keys_str_mv | AT jasonhew rituximabmonotherapyinthemanagementofararecaseofanhivassociatedlymphoproliferativedisorder AT fauziarana rituximabmonotherapyinthemanagementofararecaseofanhivassociatedlymphoproliferativedisorder AT louisezhou rituximabmonotherapyinthemanagementofararecaseofanhivassociatedlymphoproliferativedisorder |